Macrocure (MCUR) Misses Q4 EPS by 10c, Offers Guidance

Macrocure (NASDAQ: MCUR) reported Q4 EPS of ($0.42), $0.10 worse than the analyst estimate of ($0.32).

Guidance

We expect cash used for ongoing operating activities in 2015 will be $21-$25 million, reflecting anticipated expenditures to complete our current phase III clinical trials in process this year. This range excludes approximately $4 million in potential capital expenditures in 2015 primarily for our new U.S. manufacturing facility; the exact timing of such capital expenditures is yet to be determi

For earnings history and earnings-related data on Macrocure (MCUR) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• SeaStar Medical (ICU) Misses Q1 EPS by 4c
• Nortech Systems, Inc. (NSYS) Tops Q2 EPS by 11c